Drug shortages aren’t just inconveniences-they’re life-or-death emergencies. In 2024, the U.S. hit a record 323 active drug shortages, with over 270 still unresolved by the end of the year. Hospitals are scrambling. Pharmacists are spending 10+ hours a week just tracking supplies. Cancer patients skip doses because their chemo drug isn’t available. And yet, federal efforts to fix this have been patchy, contradictory, and often too little, too late.

What’s Actually Being Done?

The centerpiece of the current federal strategy is the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), launched in 2020 and dramatically expanded under Executive Order 14178 in August 2025. Instead of stockpiling finished drugs-which expire quickly and cost more-the government is now hoarding the raw chemical building blocks: active pharmaceutical ingredients (APIs). Why? Because APIs last 3 to 5 years longer than pills or injections, and they’re 40-60% cheaper to store. The goal is to have enough API on hand to quickly manufacture 26 critical drugs when a shortage hits-things like antibiotics, anesthetics, and cancer meds.

But here’s the catch: these 26 drugs represent less than 2% of all medications in shortage. The FDA’s own data shows that oncology drugs alone account for 31% of all shortages, yet only 4% of SAPIR’s targets are cancer medications. Meanwhile, 98% of shortage incidents involve drugs not even on this list. Experts like Dr. Peter Pitts call this approach dangerously narrow. Stockpiling a few ingredients won’t stop a shortage of insulin, heart meds, or neonatal antibiotics if those aren’t included.

The Data Problem

How do you fix something if you can’t measure it? That’s the core issue with federal efforts. The FDA reports 98 active shortages as of late 2024. The American Hospital Association says 277. Why the gap? Because agencies use different methods. The FDA only counts shortages that are confirmed and ongoing. Hospitals count every time a drug runs out-even if it’s for one day.

And reporting? It’s broken. Manufacturers are legally required to notify the FDA six months before a shortage, but only 58% actually do. Small manufacturers-those with under 50 employees-fail to report 82% of the time. The FDA issued just 17 warning letters between 2020 and 2024 for non-reporting. In the EU, under similar rules, they issued 142. That’s not a coincidence-it’s a policy failure.

The new HHS Draft Action Plan tries to fix this with a National Medical Countermeasures Inventory dashboard. It’s supposed to give real-time visibility into supply chains. But as of Q3 2025, only 35% of ASPR’s recommended interventions have been adopted across agencies. Half the states still haven’t set up the required supply chain mapping. Rural hospitals say it takes 3 to 6 months just to get their IT systems ready.

Manufacturing: The Real Bottleneck

Most drug shortages don’t happen because of bad weather or a truck breakdown. They happen because one factory makes 70% of a drug-and if that factory shuts down, the whole country goes without.

Just three companies control 68% of the U.S. sterile injectable market. And 78% of sterile injectable production is concentrated in only five facilities nationwide. One equipment failure. One contamination. One power outage. And you’ve got a national crisis.

The government’s answer? Build more factories. In 2024, the FDA approved 56 new manufacturing sites. But 42% of them were overseas-in Ireland, Singapore, India. That’s not reshoring. That’s just moving the problem elsewhere.

Even when companies try to build here, the system fights them. It takes 28 to 36 months for the FDA to approve a new U.S.-based API facility. In the EU? 18 to 24 months. That’s not safety-it’s bureaucracy. The $285 million in CHIPS Act funding announced in September 2025 sounds big. But industry analysts say it covers less than 5% of what’s needed to make a real dent.

What’s Missing: The Economic Reality

Here’s the truth no one wants to say out loud: we don’t have shortages because we can’t make drugs. We have shortages because no one wants to make them.

Think about it. A vial of saline costs $0.50. A vial of a new cancer drug costs $12,000. Which one do you think manufacturers prioritize? The answer is obvious. And when a drug has thin margins, companies don’t invest in backup equipment, redundant supply chains, or excess inventory. They cut costs to the bone.

That’s why the FDA’s Early Notification Pilot Program worked so well. Hospitals that participated saw shortages last 28% less time. Why? Because they were forced to report problems early. Early warning = early fix. But the current administration has weakened mandatory reporting. Meanwhile, the EU requires all member states to maintain minimum stockpiles. No surprises. No panic.

And now, federal funding for innovation is shrinking. NIH’s drug development budget dropped 18% from 2024 to 2025. That’s the pipeline for next-gen manufacturing-continuous production, AI-driven quality control, on-demand synthesis. Without investment here, we’re stuck in the 1990s.

What’s Working? Small Wins

Not all hope is lost. The FDA’s new Enhanced Shortage Monitoring System, launched in November 2025, uses AI to predict shortages 90 days in advance with 82% accuracy. It pulls data from shipping logs, hospital orders, and manufacturing batch records. Early results show hospitals using it are getting alerts before supplies run out-giving them time to find alternatives or adjust treatment plans.

The FDA is also fast-tracking second-source manufacturers. Fourteen applications are already in the pipeline. If approved, they could add backup production for eight of the most critical shortage-prone drugs by mid-2026. That’s real progress.

And then there’s H.R.5316, the Drug Shortage Act. It’s still in Congress, but if passed, it would allow pharmacists to use urgently needed compounded drugs without waiting for full FDA approval. Right now, when a lifesaving drug vanishes, hospitals have to wait weeks for a legal workaround. This bill could cut that time to days.

The Human Cost

Behind every statistic is a patient. A cancer patient who had to switch to a less effective drug because her usual chemo wasn’t available. A newborn in the NICU whose antibiotic ran out, forcing doctors to use a riskier alternative. A diabetic who skipped an insulin dose because the pharmacy couldn’t get it in.

Hospitals are spending an average of $1.2 million a year just managing shortages. Pharmacists are making 41% more medication errors due to last-minute substitutions. And 29% of Americans have skipped doses because they couldn’t get their meds-not because they couldn’t afford them, but because they simply weren’t there.

One pharmacist on Reddit described having to compound cisplatin from raw chemicals because the finished product was gone. That’s not medicine. That’s improvisation under pressure. And it’s happening in hospitals across the country.

Where Do We Go From Here?

The federal government isn’t ignoring drug shortages. But its actions are misaligned with the problem. Stockpiling APIs helps in emergencies-but it doesn’t prevent them. Building more factories helps-but only if we fix the approval delays and economic disincentives. Mandating reporting helps-but only if we enforce it.

The real solution isn’t one policy. It’s a system:

• Expand the SAPIR list to cover the top 100 shortage drugs, not just 26.
• Require mandatory reporting with real penalties for non-compliance.
• Fast-track approval for second-source manufacturers and domestic API facilities.
• Incentivize production of low-margin essential drugs through Medicare payments or tax credits.
• Invest in continuous manufacturing technology so we can produce drugs faster, cheaper, and more reliably.

Right now, we’re fighting fires with buckets. We need a fire hose. And we need it before the next crisis hits.